Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
International Chemical Investors Group (ICIG) will take over Roche’s Colorado API plant in a bid to gain footing in the peptide manufacturing industry.
The CEO of Covance has warned it will be “very, very difficult” for CROs expanding through M&A to integrate assets, and the process could see clients go elsewhere.
INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.
CRO financial results season begins this week amid reports PPD could be sold, with other service providers and private equity viewed as potential bidders.
US contract research organisation (CRO) PRA International claims it intends to “reshape how the industry manages trials” after acquiring Indian eClinical software developer, Kinship Technologies, for an undisclosed amount.
Last week non-clinical CRO CIT bought Canadian counterpart LAB Research. Outsourcing-pharma.com spoke with CIT executive chairman Jean-Francois Le Bigot about the deal and the plan going forward.
The top seven CROs will have captured half the market by 2015 as big pharma, including Pfizer, enters into strategic relationships with major players, Jeffries & Company said.
French preclinical contract research organisation (CRO) CIT has said it will buy Canadian counterpart LAB Research in a deal that would rescue the Quebec-based firm from the receivers.
Michigan, US-based clinical research organisation (CRO), Imperial, has completed the acquisition of clinical trial specialists, D. Anderson & Company for an undisclosed fee.
US-based Numira Biosciences has expanded its imaging and pre-clinical services portfolio after acquiring the efficacy pharmacology operating unit of Ricerca Biosciences.
QPS Holdings has acquired Taiwan’s Center of Toxicology and Preclinical Sciences (CTPS), continuing its expansion in the region’s rapidly expanding drug development sector.
Big pharma outsourcing will become much bolder in the next 12-18 months as companies attempt to “dramatically attack cost structures”, according to the Covance CEO.
The contract service market failed to recover as hoped in 2010 and consequently many companies made cutbacks. Outsourcing-Pharma rounds up five of the most read of 2010.
Outsourcing-Pharma presents a round up five of our top articles on strategic partnering, which continued apace in 2010, including deals by Covance, PPD and Parexel.
PRA has relocated its Poland-based early development services and product registration teams into a larger shared office after achieving “solid increases in the placement of clinical studies”.
US based healthcare distributer, Cardinal Health, has announced the $470m acquisition of privately held healthcare distribution business Zuellig Pharma China, known locally as Yong Yu.
Kendle recorded a 64 per cent drop in Q3 operating income and expects its strategic review of early stage, which will establish a fair value and consider all options, to be complete next quarter.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
